American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Medicare Patients with Advanced Systemic Mastocytosis Have a Higher Financial Burden and Use More Healthcare Resources

ASH 2021 – Systemic Mastocytosis: Wrap-Up

Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs. Read More ›

Clinical Outcomes Based on Treatment Approach in Secondary AML with Prior Hypomethylating Agent Exposure

ASH 2021 – AML

Patients with treated secondary AML and prior hypomethylating exposure derived significant clinical benefit from hypomethylating agents plus venetoclax therapy compared with chemotherapy-based approaches. Read More ›

Assessment of Prognostic Scoring Tools for Systemic Mastocytosis in a Real-World Setting

ASH 2021 – Systemic Mastocytosis: Wrap-Up

Clinical trials in systemic mastocytosis have led to the development of new prognostic scoring systems. Although effective in a controlled study, their usefulness in identifying high-risk patients in a real-world clinical setting requires further evaluation. Read More ›

New Study Investigates Safety and Efficacy of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

ASH 2021 – Systemic Mastocytosis: Wrap-Up

Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis. Read More ›

Clinical Outcomes of Liposomal Daunorubicin/Cytarabine (CPX-351) versus HMA + Venetoclax As Frontline Therapy in Newly Diagnosed AML

ASH 2021 – AML

In a retrospective analysis, upfront liposomal daunorubicin/cytarabine treatment was shown to accord an overall survival advantage compared with HMA + venetoclax, which, however, did not extend to complete response rates and recurrence-free survival. Read More ›

Magrolimab + Azacitidine-Venetoclax in Newly Diagnosed Patients with High-Risk AML or Those Older/Unfit

ASH 2021 – AML

Triplet combination of the anti-CD47 antibody magrolimab + azacitidine and venetoclax was safe and yielded high CR/CRi rates in newly diagnosed AML patients. Read More ›

Cusatuzumab plus Venetoclax and Azacitidine in Patients with Previously Untreated AML Ineligible for Intensive Chemotherapy

ASH 2021 – AML

Addition of the anti-CD70 antibody cusatuzumab to current standard-of-care venetoclax/azacitidine was generally well-tolerated and showed promising antileukemic activity in elderly patients with untreated AML. Read More ›

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive AML

ASH 2021 – AML

Triplet combination of IMGN632 (an αCD123 ADC) plus azacitidine and venetoclax was associated with a manageable safety profile and promising antileukemic activity in relapsed/refractory AML patients. Read More ›

Venetoclax plus Cladribine/Low-Dose AraC Alternating with 5-Azacitidine in Older and Unfit Patients with Newly Diagnosed AML

ASH 2021 – AML

Low-intensity regimen of venetoclax plus cladribine/low-dose AraC alternating with azacitidine was well-tolerated and produced high response rates with durable MRD-negative remissions among older/unfit patients with newly diagnosed AML. Read More ›

Novel CD7-Targeted CAR-T Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia

ASH 2021 – AML

CD7-targeted CAR-T therapy was associated with a manageable safety profile and produced complete remission in patients with CD7-positive mixed phenotype acute leukemia. Read More ›

American Society of Hematology (ASH)

Page 8 of 44